• Schrödinger Sets Course for IPO to Support Growing Internal Pipeline

    14 days ago - By Xconomy

    Scan the landscape of experimental medicines in development today and you'll spot Schrödinger's handiwork. The company's software has helped discover compounds that are now advancing in the pipelines of several drug developers. Schrödinger isn't shying away from that work. But as it continues building its own drug pipeline, it's now laying out plans to go public. In documents filed with securities regulators, the New York company has set a preliminary $100 million goal for its IPO. Schrödinger has developed software intended to make the process of discovering and developing drugs faster...
    Read more ...